Trimethaphan

Summary

Trimethaphan (CHEMBL1201329) is an approved small-molecule vasodilator agent (ATC C02BA01); indicated across 2 conditions including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02BA01
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 365.5 Da · C22H25N2OS+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201329
Name	Trimethaphan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23576
ChEBI	CHEBI:9728
ATC	C02BA01
Molecular formula	C22H25N2OS+
Molecular weight	365.5
InChIKey	CHQOEHPMXSHGCL-UHFFFAOYSA-N

SMILES: C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5

IUPAC name: 3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one

ChEBI definition: A complex heterocyclic sulfonium compound with an imidazolium core, used to treat hypertension.

Pharmacological roles (ChEBI): vasodilator agent, antihypertensive agent, anaesthesia adjuvant, nicotinic antagonist.

Also known as: Trimetaphan, Trimethaphan, Trimethaphan cation, Trimethaphan ion, TRIMETHAPHAN

Parent form; salt/anhydrous children: CHEMBL1245

Patent coverage: 1 distinct patent families (1 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Acetylcholine receptor subunit alpha.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P02710	5.15	IC50	7070	nM	CHEMBL_ACT_12574644

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	8
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02425566	PHASE1	ACTIVE_NOT_RECRUITING	Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension
NCT02726711	PHASE1	ACTIVE_NOT_RECRUITING	Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
NCT00179023	PHASE1	COMPLETED	The Autonomic Nervous System and Obesity
NCT00580619	PHASE1	COMPLETED	Autonomic Nervous System and Chronic Fatigue Syndrome
NCT01122407	PHASE1	COMPLETED	Pathophysiology of Cardiometabolic Risk Factors in African Americans
NCT01137253	PHASE1	COMPLETED	Autonomic Nervous System and Nitric Oxide Interactions
NCT02245230	PHASE1	TERMINATED	Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
NCT03028571	PHASE1	WITHDRAWN	Autonomic Blockade and Endogenous Glucose Production
NCT00178919	Not specified	COMPLETED	Nitric Oxide and the Autonomic Nervous System

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).